A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Low-Grade Astrocytomas—Final Report (Protocol BT-13)

Burzynski, Stanislaw R.; Janicki, Tomasz; Burzynski, Gregory S.

doi:10.4236/jct.2016.712083

Cited by 2 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human body produces metabolites that can inhibit the growth of cancer cells. Such active metabolites can be purified from urine by reverse phase chromatography on C18, which Burzynski gave the names Antineoplastons [29]. Active components of Antineoplastons are DIs and DHIs.…”

Section: Chemo-surveillance As An Important Issue Of Wound Healingmentioning

confidence: 99%

CDA Formulations to Fulfill Cancer Moonshot and to Win the War on Cancer

Liau¹,

Craig²,

Baker³

2023

Int J Res Oncol

View full text Add to dashboard Cite

The objective of this study is to call for approval of cell differentiation agent (CDA) formulations as the right cancer drugs to save cancer patients. Moonshot was a presidential project to set a classic record of success attributable to the right approach and war on cancer was another presidential project to set a classic record of failure attributable to the wrong approach. Cancer moonshot was brought up by President Biden to urge health profession to rely on right approaches to save cancer patients. Perpetual replication of cancer cells (CCs) is the most outstanding feature of cancer. Naturally, killing of replicating CCs becomes the top choice of cancer establishments to combat cancer. Killing of CCs is actually a wrong approach of cancer therapy, because cancer is caused by wound unhealing due to the collapse of chemo-surveillance, which is a natural mechanism to ensure perfection of wound healing. Killing of CCs by cytotoxic agents promotes cancer stem cells (CSCs) to proliferate in order to repair the damages created by cytotoxic agents, eventually pushing CSCs to reach a high proportion to become unresponsive to further treatments. Killing of CCs is a wrong approach that causes the failure of cancer solution. To save cancer patients, we have to drastically change past practices. Apparently, wound healing process is the right approach of cancer therapy. Induction of terminal differentiation of PSCs is the most critical mechanism of wound healing, which is achieved by differentiation inducers (DIs) and differentiation helper inducers (DHIs). CDA is a collective term of the preparations consisting of different proportions of DIs and DHIs. Therefore, CDA formulations are the best solution of cancer to fulfill cancer moonshot and to win the war on cancer. CDA formulations display the features as pro-wound healing that can eliminate both CSCs and CCs by inducing these cells to undergo terminal differentiation, and to restore the functionality of chemo-surveillance, which is the creation of the nature to prevent the buildup of cells with abnormal MEs. A perfect cancer drug must have the ability to eliminate both CSCs and CCs, and to restore the functionality of chemo-surveillance. CDA formulations fit the description as perfect cancer drugs to fulfill cancer moonshot and to win the war on cancer.

show abstract

Section: Chemo-surveillance As An Important Issue Of Wound Healingmentioning

confidence: 99%

CDA Formulations to Fulfill Cancer Moonshot and to Win the War on Cancer

Liau¹,

Craig²,

Baker³

2023

Int J Res Oncol

View full text Add to dashboard Cite

show abstract

“…While tumor measurements were based on the contrast enhanced lesions, tumor size was also measured utilizing T2 and FLAIR images [21] [25]. The details of the required laboratory tests and follow-up studies have previously been published [11]. Adverse events (AEs) were graded according to the Common Terminology Criteria for Adverse Events (CTCAE v.3.0).…”

Section: Evaluation and Follow-upmentioning

confidence: 99%

A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Brain Tumors. Final Report (Protocol BT-10)

Burzynski¹,

Janicki²,

Burzynski³

et al. 2017

JCT

Self Cite

View full text Add to dashboard Cite

Despite dramatic progress over the last 50 years in the treatment of many childhood cancers, primary brain tumors remain the leading cause of death in pediatric oncology. This phase II study evaluated the efficacy and safety of Antineoplastons A10 and AS2-1 given in combination (ANP). Thirty-four patients, with a median age of 10.4 years, were enrolled in the study. Thirty-two patients (94.1%), were Caucasians while 21 (61.8%) were female and 13 were male (38.2%). Twenty-four patients (70.6%) suffered from a brainstem glioma (BSG) or high-grade tumor. Ten patients (29.4%) suffered from a low-grade tumor. A distinct sub-group of three patients with low grade tumors had a ganglioglioma (GG). Eighty-two percent of patients had failed standard treatment. Daily ANP was administered by IV infusion, every four hours, until an objective response (OR) was documented, and then for an additional eight months. The median doses of A10 and AS2-1 were 11.64 g/kg/d and 0.45 g/kg/d, respectively. A complete response (CR) was documented in two patients (5.9%), a partial response (PR) in four patients (11.8%), and stable disease (SD) in six patients (17.6%). Objective responses were observed in diffuse intrinsic pontine glioma (DIPG), thalamic pilocytic astrocytoma with brainstem involvement, ganglioglioma and pilocytic astrocytoma. Six-month progression-free survival (PFS) was 35.3%. Overall survival (OS) at two and five years was 37.6% and 34.5%, respectively. Two patients experienced grade 4 hypernatremia while three experienced grade 3 hypokalemia. In this group of patients, ANP showed good efficacy and an acceptable toxicity profile.

show abstract

A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Low-Grade Astrocytomas—Final Report (Protocol BT-13)

Cited by 2 publications

References 32 publications

CDA Formulations to Fulfill Cancer Moonshot and to Win the War on Cancer

CDA Formulations to Fulfill Cancer Moonshot and to Win the War on Cancer

A Phase II Study of Antineoplastons A10 and AS2-1 in Children with Brain Tumors. Final Report (Protocol BT-10)

Contact Info

Product

Resources

About